The Board of Directors of UCB and CEO Roch Doliveux have annoounced the implementation of its CEO succession plan.
Jean-Christophe Tellier, currently UCB’s Executive Vice President, Biopharma Brands and Solutions, will be appointed Chief Executive Officer-Elect and Chairman of the Executive Committee as of March 1, 2014. Jean-Christophe Tellier will also be proposed to be appointed as a member of the Board of Directors at the next Annual General Meeting of Shareholders on April 24, 2014.
This change is the result of a long and well thought through succession plan to ensure necessary experience and knowledge transfer. It creates the best conditions for the company’s future growth allowing it, together with its 8500 colleagues, to deliver on UCB’s commitment to patients.
“In the last 10 years, under Roch Doliveux’s leadership, UCB has evolved from a diversified chemical company into a global biopharmaceutical leader”, said Gerhard Mayr, Chairman of UCB’s Board of Directors. “In that journey UCB has surmounted the patent cliff of its former blockbuster products and successfully launched three new core medicines - Cimzia®, Vimpat® and Neupro®. We have also accelerated our growth in emerging markets and Japan, while continuously enhancing our R&D productivity to build today’s promising pipeline. Roch has put everything in place to prepare UCB for its next phase. We wish to express our gratitude for everything he has done for UCB and the patients who rely on our innovative products worldwide. We are confident that Jean-Christophe Tellier will continue to drive UCB to provide superior and sustainable value for patients. He and Roch will continue to work together throughout 2014 to ensure a smooth handover before Jean-Christophe takes the helm of UCB as of January 1, 2015.”
Roch Doliveux, CEO of UCB, said “UCB is entering an important new growth era: our rich late-stage pipeline is poised to reach pivotal milestones from the second half of 2014 through mid- 2016. Leadership continuity is critical to ensuring the successful launch of these important products in the severe disease areas of osteoporosis, lupus and epilepsy. Since joining UCB in 2011, Jean-Christophe has played a key role in UCB’s successes, and he has been instrumental in helping establish our current strategy. Jean-Christophe’s distinguished 25-year career in the biopharmaceutical industry, his patient-centric approach, his medical background as a rheumatologist and his passion for developing talent make him the perfect candidate to lead the company through its next phase of evolution. We are fortunate to have found UCB’s future leader internally; it has been a privilege for me to work with the Board to identify and develop my successor”.
UCB has planned an orderly handover period throughout the remainder of 2014 with Jean-Christophe Tellier working alongside current CEO, Roch Doliveux, to ensure a seamless transition when Jean-Christophe Tellier becomes Chief Executive Officer of UCB on January 1, 2015.